Recent announcements of Phone Number List successful results in two clinical trials of COVID-19 vaccines raise hopes that a return to normalcy is near. Preliminary data on the new vaccines from Pfizer/ and are very encouraging and suggest Phone Number List that their emergency approval is imminent. And more recent news about the efficacy (albeit slightly less so) of a vaccine co-developed by AstraZeneca and the University of Oxford also gives reason to hope for further developments. In theory, the arrival of a safe and effective vaccine Phone Number List would be the beginning of the end of the covid-19 pandemic.
But in reality, we have not begun Phone Number List to achieve what is really needed: a " people's vaccine ".», which is distributed equitably and free of charge to all who need it. Of course, we must praise everything that has been done to be able to create vaccines in just a few months. It has been a huge technological leap Phone Number List for humanity. But that leap was made from a springboard of decades of large-scale public investment in research and development. The main vaccine candidates are generally based on preparing the immune system to detect the Phone Number List spike protein, a technique made possible by years of research at the US National Institutes of Health.
More recently, received $445 the Phone Number List German government, and received $1 million from the Coalition for Epidemic Preparedness Innovations and more than $1 billion from two U.S. agencies: the Biomedical Advanced Research and Development Authority and the Research Projects Agency. Defense Advanced. AstraZeneca-Oxford's Phone Number List vaccine received more than 1 billion pounds ($1.3 billion) of public funding . But for technological advances to become " health for all ", collectively created innovations need to be Phone Number List governed by the public interest and not by private gain. This is particularly true in the case of vaccine development, manufacturing, and distribution in the.